search
Back to results

THE EFFECT OF ARGININE AND GLUTAMINE ON COVID-19 PATIENTS OUTCOME: A RANDOMIZED CLINICAL TRIAL

Primary Purpose

COVID-19

Status
Completed
Phase
Phase 3
Locations
Indonesia
Study Type
Interventional
Intervention
Neomune
Sponsored by
Universitas Sriwijaya
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for COVID-19 focused on measuring COVID-19, Oral Nutrition Supplement

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Patients confirmed positive for COVID-19 Age over 17 years The patient can take food orally Exclusion Criteria: Patients with restricted fluid intake Patients who cannot take food orally suffering from diabetes mellitus and kidney failure

Sites / Locations

  • Dr. M. Djamil General Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

intervention group

control group

Arm Description

The intervention group was given a High-Calorie High-Protein + ONS diet containing 4.8 g arginine and 2 g glutamine, namely Neomune 2x 200 cc, purchased from Otsuka Pharmaceutical Co., Ltd

the control was administered with a High-Calorie High-Protein diet + ONS hospital standard.

Outcomes

Primary Outcome Measures

length of stay
length of stay of patients in hospital
Outcome
Outcome Measures of patients (discharge or dead)
ICU Admission
A patient is likely to be admitted to ICU during intervention period

Secondary Outcome Measures

Il-6 and CRP Levels
Il-6 and CRP Levels during hospitalization

Full Information

First Posted
August 19, 2023
Last Updated
August 19, 2023
Sponsor
Universitas Sriwijaya
Collaborators
M. Djamil General Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT06004375
Brief Title
THE EFFECT OF ARGININE AND GLUTAMINE ON COVID-19 PATIENTS OUTCOME: A RANDOMIZED CLINICAL TRIAL
Official Title
THE EFFECT OF ARGININE AND GLUTAMINE ON COVID-19 PATIENTS OUTCOME: A RANDOMIZED CLINICAL TRIAL
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Completed
Study Start Date
May 1, 2021 (Actual)
Primary Completion Date
May 30, 2023 (Actual)
Study Completion Date
May 30, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Universitas Sriwijaya
Collaborators
M. Djamil General Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The goal of this clinical trial is to determine effect of arginine and glutamine on outcome of COVID-19 patients. The main questions it aims to answer are: -to test the effect of oral nutritional supplements containing arginine and glutamine on covid-19 patients outcome Dr. M. Djamil General Hospital Padang Participants will given ONS containing arginine and glutamine. Researchers will compare intervention group with control group to see if ONS affected outcome of COVID-19 patients

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
COVID-19
Keywords
COVID-19, Oral Nutrition Supplement

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
20 (Actual)

8. Arms, Groups, and Interventions

Arm Title
intervention group
Arm Type
Experimental
Arm Description
The intervention group was given a High-Calorie High-Protein + ONS diet containing 4.8 g arginine and 2 g glutamine, namely Neomune 2x 200 cc, purchased from Otsuka Pharmaceutical Co., Ltd
Arm Title
control group
Arm Type
Active Comparator
Arm Description
the control was administered with a High-Calorie High-Protein diet + ONS hospital standard.
Intervention Type
Dietary Supplement
Intervention Name(s)
Neomune
Intervention Description
Neomune containing 4.8 g arginine and 2 g glutamine
Primary Outcome Measure Information:
Title
length of stay
Description
length of stay of patients in hospital
Time Frame
3 months
Title
Outcome
Description
Outcome Measures of patients (discharge or dead)
Time Frame
3 months
Title
ICU Admission
Description
A patient is likely to be admitted to ICU during intervention period
Time Frame
3 months
Secondary Outcome Measure Information:
Title
Il-6 and CRP Levels
Description
Il-6 and CRP Levels during hospitalization
Time Frame
3 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients confirmed positive for COVID-19 Age over 17 years The patient can take food orally Exclusion Criteria: Patients with restricted fluid intake Patients who cannot take food orally suffering from diabetes mellitus and kidney failure
Facility Information:
Facility Name
Dr. M. Djamil General Hospital
City
Padang
State/Province
West Sumatera
ZIP/Postal Code
25176
Country
Indonesia

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

THE EFFECT OF ARGININE AND GLUTAMINE ON COVID-19 PATIENTS OUTCOME: A RANDOMIZED CLINICAL TRIAL

We'll reach out to this number within 24 hrs